Wedbush Upgrades Replimune Group (REPL) to Outperform
buy
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
buy
What happened, with direct paths to the underlying reporting
Wedbush upgrades REPL to Outperform; target $12; current price $5.41.
Target: $12
Posted price: $5.41
Analyst firm: Wedbush
Analyst: Robert Driscoll
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.